Is It Time To Reassess Genscript Biotech (SEHK:1548) After Its Recent Share Price Recovery?

Simply Wall St.04-25 02:11

If you are wondering whether Genscript Biotech at HK$13.85 is priced for opportunity or already reflecting the story, this valuation breakdown is designed to give you a clear starting point. The stock...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630827551?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-04-25 02:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630827551","market":"nz","top_or_hot":-1,"title":"Is It Time To Reassess Genscript Biotech (SEHK:1548) After Its Recent Share Price Recovery?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Genscript Biotech at HK$13.85 is priced for opportunity or already reflecting the story, this valuation breakdown is designed to give you a clear starting point. The stock...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/is-it-time-to-reassess-genscript-biotech-sehk1548-after-its\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Reassess Genscript Biotech (SEHK:1548) After Its Recent Share Price Recovery?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Reassess Genscript Biotech (SEHK:1548) After Its Recent Share Price Recovery?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-25 02:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/is-it-time-to-reassess-genscript-biotech-sehk1548-after-its><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Genscript Biotech at HK$13.85 is priced for opportunity or already reflecting the story, this valuation breakdown is designed to give you a clear starting point. The stock...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/is-it-time-to-reassess-genscript-biotech-sehk1548-after-its\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/is-it-time-to-reassess-genscript-biotech-sehk1548-after-its","article_id":"2630827551","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/is-it-time-to-reassess-genscript-biotech-sehk1548-after-its","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630827551","pubTimestamp":1777054273,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Genscript Biotech at HK$13.85 is priced for opportunity or already reflecting the story, this valuation breakdown is designed to give you a clear starting point.\nThe stock has returned 0.7% over the last 7 days, 25.8% over the last 30 days, 8.3% year to date, and 25.2% over 1 year, while the 3 year and 5 year returns sit at 32.8% and 23.1% declines respectively.\nThese mixed returns mean context really matters. Recent company updates, financing decisions,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4581":"高盛持仓","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1576":"医药外包概念","BK1583":"高瓴概念","BK1141":"生命科学工具和服务","XBI":"SPDR S&P Biotech ETF","01548":"金斯瑞生物科技","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4588":"碎股"},"translate_title":"金斯瑞生物科技（SEHK：1548）近期股价回升后，是时候重新评估它了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"XBI":1.5,"01548":0.9},"content_text":"If you are wondering whether Genscript Biotech at HK$13.85 is priced for opportunity or already reflecting the story, this valuation breakdown is designed to give you a clear starting point. The stock has returned 0.7% over the last 7 days, 25.8% over the last 30 days, 8.3% year to date, and 25.2% over 1 year, while the 3 year and 5 year returns sit at 32.8% and 23.1% declines respectively. These mixed returns mean context really matters. Recent company updates, financing decisions, partnerships or regulatory developments can help explain why sentiment has shifted over different time frames. Understanding what has been driving attention toward Genscript Biotech, whether optimism or caution, can make a big difference to how you interpret the current share price. On Simply Wall St's framework, Genscript Biotech currently scores 6 out of 6 on valuation checks. The sections ahead walk through the standard valuation methods used to reach that result before finishing with a more complete way to think about what the stock could be worth.  Find out why Genscript Biotech's 25.2% return over the last year is lagging behind its peers. AdvertisementApproach 1: Genscript Biotech Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today’s value. For Genscript Biotech, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow sits at about $81.65 million. Analysts provide specific forecasts for the coming years, and Simply Wall St then extends those projections, with the ten year outlook including an estimated free cash flow of $526.52 million in 2035. Aggregating and discounting these projected cash flows results in an estimated intrinsic value of about HK$25.09 per share. Compared with the current share price of HK$13.85, the DCF output suggests the shares trade at a 44.8% discount. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Genscript Biotech is undervalued by 44.8%. Track this in your watchlist or portfolio, or discover 228 more high quality undervalued stocks. 1548 Discounted Cash Flow as at Apr 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Genscript Biotech. Approach 2: Genscript Biotech Price vs Sales For companies where earnings may not fully capture the business, the P/S ratio is often a helpful cross check, because it compares what the market is paying for each unit of revenue. In general, higher growth expectations or lower perceived risk can justify a higher \"normal\" P/S multiple, while slower growth or higher uncertainty can point to a lower one. That is why it helps to look at a few benchmarks rather than the headline number in isolation. Genscript Biotech currently trades on a P/S ratio of 4.03x. This sits close to the Life Sciences industry average P/S of 3.85x and well below the peer group average of 13.79x. Simply Wall St also calculates a proprietary \"Fair Ratio\" for Genscript Biotech of 4.50x, which reflects factors such as the company’s growth profile, risk characteristics, profit margins, industry and market cap. This Fair Ratio is more tailored than a simple comparison with peers or the broad industry, because it adjusts for business quality and risk rather than assuming every company deserves the same multiple. With Genscript Biotech at 4.03x versus a Fair Ratio of 4.50x, the P/S check points to the shares trading below that customised benchmark. Result: UNDERVALUED SEHK:1548 P/S Ratio as at Apr 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 95 top founder-led companies. Upgrade Your Decision Making: Choose your Genscript Biotech Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story to your numbers by linking your view of Genscript Biotech’s future revenue, earnings and margins to a forecast, a Fair Value, and then comparing that Fair Value with the current share price to help you decide if and when to act. Available on the Community page and used by millions of investors, Narratives are kept current as fresh news or earnings are released. They make it easy to see how one investor might lean toward the higher HK$21.01 fair value with a story built around European mRNA expansion and AI enabled efficiency, while another might anchor closer to HK$15.88 with more weight on competition, automation costs and reliance on key subsidiaries. Do you think there's more to the story for Genscript Biotech? Head over to our Community to see what others are saying! SEHK:1548 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630827551","isCrawlerRequest":true}